157 related articles for article (PubMed ID: 37908209)
1. Denosumab-Induced Rebound Hypercalcemia Treated With Bisphosphonates in a Pediatric Patient.
Gandolfi A; Shaaban S
JCEM Case Rep; 2023 Sep; 1(5):luad133. PubMed ID: 37908209
[TBL] [Abstract][Full Text] [Related]
2. Osteonecrosis of the Jaw and Rebound Hypercalcemia in Young People Treated With Denosumab for Giant Cell Tumor of Bone.
Uday S; Gaston CL; Rogers L; Parry M; Joffe J; Pearson J; Sutton D; Grimer R; Högler W
J Clin Endocrinol Metab; 2018 Feb; 103(2):596-603. PubMed ID: 29211870
[TBL] [Abstract][Full Text] [Related]
3. Aneurysmal bone cyst: results of an off label treatment with Denosumab.
Dürr HR; Grahneis F; Baur-Melnyk A; Knösel T; Birkenmaier C; Jansson V; Klein A
BMC Musculoskelet Disord; 2019 Oct; 20(1):456. PubMed ID: 31630689
[TBL] [Abstract][Full Text] [Related]
4. Long-term follow up after denosumab treatment for osteoporosis - rebound associated with hypercalcemia, parathyroid hyperplasia, severe bone mineral density loss, and multiple fractures: a case report.
Maugars Y; Guillot P; Glémarec J; Berthelot JM; Le Goff B; Darrieutort-Laffite C
J Med Case Rep; 2020 Aug; 14(1):130. PubMed ID: 32792004
[TBL] [Abstract][Full Text] [Related]
5. Mitigating the Denosumab-Induced Rebound Phenomenon with Alternating Short- and Long-Acting Anti-resorptive Therapy in a Young Boy with Severe OI Type VI.
Seale E; Molina MO; Carsen S; Sheffield H; Koujok K; Robinson ME; Feber J; Smit K; Page M; Walker S; Khan N; Konji VN; Rauch F; Ward LM
Calcif Tissue Int; 2023 May; 112(5):613-620. PubMed ID: 36867194
[TBL] [Abstract][Full Text] [Related]
6. Rebound hypercalcemia post-denosumab cessation in metastatic breast cancer.
Wang R; Renouf DA
Osteoporos Int; 2022 Jul; 33(7):1625-1629. PubMed ID: 35286436
[TBL] [Abstract][Full Text] [Related]
7. Severe hypercalcemia following denosumab treatment in a juvenile patient.
Setsu N; Kobayashi E; Asano N; Yasui N; Kawamoto H; Kawai A; Horiuchi K
J Bone Miner Metab; 2016 Jan; 34(1):118-22. PubMed ID: 26056018
[TBL] [Abstract][Full Text] [Related]
8. Use of Denosumab in Children With Osteoclast Bone Dysplasias: Report of Three Cases.
Upfill-Brown A; Bukata S; Bernthal NM; Felsenfeld AL; Nelson SD; Singh A; Wesseling-Perry K; Eilber FC; Federman NC
JBMR Plus; 2019 Oct; 3(10):e10210. PubMed ID: 31687646
[TBL] [Abstract][Full Text] [Related]
9. Mineral and Bone Consequences of High Dose Denosumab Therapy to Treat an Aneurysmal Bone Cyst, a Child Case Report.
Del Sindaco G; Berlanga P; Brugières L; Thebault E; Mantovani G; Wicart P; Linglart A
Front Endocrinol (Lausanne); 2021; 12():698963. PubMed ID: 34335473
[TBL] [Abstract][Full Text] [Related]
10. Hypercalcaemia after treatment with denosumab in children: bisphosphonates as an option for therapy and prevention?
Sydlik C; Dürr HR; Pozza SB; Weißenbacher C; Roeb J; Schmidt H
World J Pediatr; 2020 Oct; 16(5):520-527. PubMed ID: 32776272
[TBL] [Abstract][Full Text] [Related]
11. Surgical Management and Denosumab for Aneurysmal Bone Cysts of the Spine in an Australian Tertiary Paediatric Centre.
Vanderniet JA; Tsinas D; Wall CL; Girgis CM; London K; Keane C; Briody J; Hibbert S; Poon M; Padhye B; Biggin A; Dalla-Pozza L; Gray RJ; Munns CF
Calcif Tissue Int; 2023 May; 112(5):592-602. PubMed ID: 36810677
[TBL] [Abstract][Full Text] [Related]
12. Safety and Efficacy of Denosumab in Children With Osteogenesis Imperfecta-the First Prospective Comparative Study.
Liu J; Lin X; Sun L; Zhang Q; Jiang Y; Wang O; Xing X; Xia W; Li M
J Clin Endocrinol Metab; 2024 Jun; 109(7):1827-1836. PubMed ID: 38198649
[TBL] [Abstract][Full Text] [Related]
13. Hypercalcemia following discontinuation of denosumab therapy: A systematic review.
Horiuchi K; Kobayashi E; Mizuno T; Susa M; Chiba K
Bone Rep; 2021 Dec; 15():101148. PubMed ID: 34825020
[TBL] [Abstract][Full Text] [Related]
14. Denosumab treatment in aneurysmal bone cyst: Evaluation of nine cases.
Kurucu N; Akyuz C; Ergen FB; Yalcin B; Kosemehmetoglu K; Ayvaz M; Varan A; Aydin B; Kutluk T
Pediatr Blood Cancer; 2018 Apr; 65(4):. PubMed ID: 29286564
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms of acute hypercalcemia in pediatric patients following the interruption of Denosumab.
Deodati A; Fintini D; Levtchenko E; Rossi M; Ubertini G; Segers H; Battafarano G; Cappa M; Del Fattore A
J Endocrinol Invest; 2022 Jan; 45(1):159-166. PubMed ID: 34216372
[TBL] [Abstract][Full Text] [Related]
16. Bisphosphonates and other bone agents for breast cancer.
Wong MH; Stockler MR; Pavlakis N
Cochrane Database Syst Rev; 2012 Feb; (2):CD003474. PubMed ID: 22336790
[TBL] [Abstract][Full Text] [Related]
17. Critical hypercalcemia following discontinuation of denosumab therapy for metastatic giant cell tumor of bone.
Gossai N; Hilgers MV; Polgreen LE; Greengard EG
Pediatr Blood Cancer; 2015 Jun; 62(6):1078-80. PubMed ID: 25556556
[TBL] [Abstract][Full Text] [Related]
18. Acute hypercalcemia and excessive bone resorption following anti-RANKL withdrawal: Case report and brief literature review.
Roux S; Massicotte MH; Huot Daneault A; Brazeau-Lamontagne L; Dufresne J
Bone; 2019 Mar; 120():482-486. PubMed ID: 30572144
[TBL] [Abstract][Full Text] [Related]
19. Hypercalcemia upon denosumab withdrawal in primary hyperparathyroidism: a case report and literature review.
Camponovo C; Aubry-Rozier B; Lamy O; Gonzalez Rodriguez E
Osteoporos Int; 2020 Dec; 31(12):2485-2491. PubMed ID: 33057735
[TBL] [Abstract][Full Text] [Related]
20. Treatment of Hypercalcemia of Malignancy.
Chakhtoura M; El-Hajj Fuleihan G
Endocrinol Metab Clin North Am; 2021 Dec; 50(4):781-792. PubMed ID: 34774248
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
